Biosketch

Véronique Baud received her PhD in Molecular Genetics in 1996, Paris, France with the highest honors. After having carried out a Post-Doc in  Michael Karin lab, UCSD, CA, USA, she set up her own independent research group at Institut Cochin, Paris, France, with the support of Fondation pour la Recherche Médicale, amorçage jeunes équipes, and was awarded a tenured research position at INSERM in 2002. She was the head of the Research Unit “NF-kappaB, Differentiation and Cancer” at the Faculté de Pharmacie, Paris, France for more than ten years. She is currently Research Director, Inserm, and joined the team of Mario Pende at INEM, Paris in 2026 as a group leader. Her research group works at the interface between cancer biology and translational research, with a focus on the alternative NF-kB signaling pathway, how it is regulated, and its contributions towards tumor development, resistance to conventional cancer therapies and relationship with metabolic reprograming in cancer cells. Véronique Baud’s recent work has revealed new biomarkers and targets for cancer treatment (several patents). She has contributed to important findings leading to publications in high impact journals (Nature, Science, Genes & Dev, PNAS, Blood,…).

Funding for the NF-κB, Metabolism, Immunity and Cancer research axis

PUI ValoCité, Université Paris Cité, SATT Erganeo, Projet de Maturation

SIRIC INSIghts Into Cancer: From Inflammation to TUmor (InSiTu)

Programme INSERM PCSI, Approches interdisciplinaires des processus oncogéniques et perspectives thérapeutiques, Apports de la physique, de la chimie et des sciences de l’ingénieur à l’oncologie (PCSI)

ARC, Sign’it, Signature en immunothérapie

Patents

1- EP24184216.0, 2024, An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large B-cell lymphoma, inventors: Baud V., Montagne A., Bertho G., Giraud, N.

2- EP22306099, 2022, Methods for detecting metabolic reprogramming of cancer towards fatty acid metabolism, inventors: Baud V.

3- Patent EP20306407, 2020, Methods and kits for classifying solid cancer-afflicted patients based on  RelB, inventors: Baud V., Eluard B.

4- Patent EP20315147.7, 2020, Induction of B-cell lymphoma cells death by a combination of antimetabolic drugs, inventors : Baud V., Thieblemont C.

5- Patent EP19305847.6, 2019, Detection of RelB activation as a prognostic marker in B-cell lymphoma; inventors: Baud V.

6- Patent EP2793026-A1; WO2014170487-A1, 2014, New method for monitoring cancer and/or inflammatory reaction based on RelB phosphorylation; Inventors : Baud V, Billot K. Licenced by the industrial Clinisciences.